HER2-negative Breast Cancer Treatment Market, Global Outlook and Forecast 2023-2029

Report ID: MMG251336 | Category: Medical Care | Pages: 69 | Format: PDF | Published Date: October 26,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
This report aims to provide a comprehensive presentation of the global market for HER2-negative Breast Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2-negative Breast Cancer Treatment. This report contains market size and forecasts of HER2-negative Breast Cancer Treatment in global, including the following market information:
Global HER2-negative Breast Cancer Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global HER2-negative Breast Cancer Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Chemotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of HER2-negative Breast Cancer Treatment include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Pfizer, GlaxoSmithKline, Novartis and Merck, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the HER2-negative Breast Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global HER2-negative Breast Cancer Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global HER2-negative Breast Cancer Treatment Market Segment Percentages, by Type, 2022 (%)
    Chemotherapy
    Surgery
    Radiation
    Hormonal therapy/endocrine therapy
Global HER2-negative Breast Cancer Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global HER2-negative Breast Cancer Treatment Market Segment Percentages, by Application, 2022 (%)
    Hosptial
    Clinic
Global HER2-negative Breast Cancer Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global HER2-negative Breast Cancer Treatment Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies HER2-negative Breast Cancer Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies HER2-negative Breast Cancer Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    AstraZeneca
    Bristol-Myers Squibb
    Eli Lilly
    Pfizer
    Novartis
    Pfizer
    GlaxoSmithKline
    Novartis
    Merck
    Eli Lilly
Outline of Major Chapters:
Chapter 1: Introduces the definition of HER2-negative Breast Cancer Treatment, market overview.
Chapter 2: Global HER2-negative Breast Cancer Treatment market size in revenue.
Chapter 3: Detailed analysis of HER2-negative Breast Cancer Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of HER2-negative Breast Cancer Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 HER2-negative Breast Cancer Treatment Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global HER2-negative Breast Cancer Treatment Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global HER2-negative Breast Cancer Treatment Overall Market Size
    2.1 Global HER2-negative Breast Cancer Treatment Market Size: 2022 VS 2029
    2.2 Global HER2-negative Breast Cancer Treatment Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top HER2-negative Breast Cancer Treatment Players in Global Market
    3.2 Top Global HER2-negative Breast Cancer Treatment Companies Ranked by Revenue
    3.3 Global HER2-negative Breast Cancer Treatment Revenue by Companies
    3.4 Top 3 and Top 5 HER2-negative Breast Cancer Treatment Companies in Global Market, by Revenue in 2022
    3.5 Global Companies HER2-negative Breast Cancer Treatment Product Type
    3.6 Tier 1, Tier 2 and Tier 3 HER2-negative Breast Cancer Treatment Players in Global Market
        3.6.1 List of Global Tier 1 HER2-negative Breast Cancer Treatment Companies
        3.6.2 List of Global Tier 2 and Tier 3 HER2-negative Breast Cancer Treatment Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global HER2-negative Breast Cancer Treatment Market Size Markets, 2022 & 2029
        4.1.2 Chemotherapy
        4.1.3 Surgery
        4.1.4 Radiation
        4.1.5 Hormonal therapy/endocrine therapy
    4.2 By Type - Global HER2-negative Breast Cancer Treatment Revenue & Forecasts
        4.2.1 By Type - Global HER2-negative Breast Cancer Treatment Revenue, 2018-2023
        4.2.2 By Type - Global HER2-negative Breast Cancer Treatment Revenue, 2024-2029
        4.2.3 By Type - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global HER2-negative Breast Cancer Treatment Market Size, 2022 & 2029
        5.1.2 Hosptial
        5.1.3 Clinic
    5.2 By Application - Global HER2-negative Breast Cancer Treatment Revenue & Forecasts
        5.2.1 By Application - Global HER2-negative Breast Cancer Treatment Revenue, 2018-2023
        5.2.2 By Application - Global HER2-negative Breast Cancer Treatment Revenue, 2024-2029
        5.2.3 By Application - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global HER2-negative Breast Cancer Treatment Market Size, 2022 & 2029
    6.2 By Region - Global HER2-negative Breast Cancer Treatment Revenue & Forecasts
        6.2.1 By Region - Global HER2-negative Breast Cancer Treatment Revenue, 2018-2023
        6.2.2 By Region - Global HER2-negative Breast Cancer Treatment Revenue, 2024-2029
        6.2.3 By Region - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America HER2-negative Breast Cancer Treatment Revenue, 2018-2029
        6.3.2 US HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.3.3 Canada HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.3.4 Mexico HER2-negative Breast Cancer Treatment Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe HER2-negative Breast Cancer Treatment Revenue, 2018-2029
        6.4.2 Germany HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.4.3 France HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.4.4 U.K. HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.4.5 Italy HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.4.6 Russia HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.4.7 Nordic Countries HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.4.8 Benelux HER2-negative Breast Cancer Treatment Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia HER2-negative Breast Cancer Treatment Revenue, 2018-2029
        6.5.2 China HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.5.3 Japan HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.5.4 South Korea HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.5.5 Southeast Asia HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.5.6 India HER2-negative Breast Cancer Treatment Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America HER2-negative Breast Cancer Treatment Revenue, 2018-2029
        6.6.2 Brazil HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.6.3 Argentina HER2-negative Breast Cancer Treatment Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa HER2-negative Breast Cancer Treatment Revenue, 2018-2029
        6.7.2 Turkey HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.7.3 Israel HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.7.4 Saudi Arabia HER2-negative Breast Cancer Treatment Market Size, 2018-2029
        6.7.5 UAE HER2-negative Breast Cancer Treatment Market Size, 2018-2029
7 HER2-negative Breast Cancer Treatment Companies Profiles
    7.1 AstraZeneca
        7.1.1 AstraZeneca Company Summary
        7.1.2 AstraZeneca Business Overview
        7.1.3 AstraZeneca HER2-negative Breast Cancer Treatment Major Product Offerings
        7.1.4 AstraZeneca HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.1.5 AstraZeneca Key News & Latest Developments
    7.2 Bristol-Myers Squibb
        7.2.1 Bristol-Myers Squibb Company Summary
        7.2.2 Bristol-Myers Squibb Business Overview
        7.2.3 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Major Product Offerings
        7.2.4 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.2.5 Bristol-Myers Squibb Key News & Latest Developments
    7.3 Eli Lilly
        7.3.1 Eli Lilly Company Summary
        7.3.2 Eli Lilly Business Overview
        7.3.3 Eli Lilly HER2-negative Breast Cancer Treatment Major Product Offerings
        7.3.4 Eli Lilly HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.3.5 Eli Lilly Key News & Latest Developments
    7.4 Pfizer
        7.4.1 Pfizer Company Summary
        7.4.2 Pfizer Business Overview
        7.4.3 Pfizer HER2-negative Breast Cancer Treatment Major Product Offerings
        7.4.4 Pfizer HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.4.5 Pfizer Key News & Latest Developments
    7.5 Novartis
        7.5.1 Novartis Company Summary
        7.5.2 Novartis Business Overview
        7.5.3 Novartis HER2-negative Breast Cancer Treatment Major Product Offerings
        7.5.4 Novartis HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.5.5 Novartis Key News & Latest Developments
    7.6 Pfizer
        7.6.1 Pfizer Company Summary
        7.6.2 Pfizer Business Overview
        7.6.3 Pfizer HER2-negative Breast Cancer Treatment Major Product Offerings
        7.6.4 Pfizer HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.6.5 Pfizer Key News & Latest Developments
    7.7 GlaxoSmithKline
        7.7.1 GlaxoSmithKline Company Summary
        7.7.2 GlaxoSmithKline Business Overview
        7.7.3 GlaxoSmithKline HER2-negative Breast Cancer Treatment Major Product Offerings
        7.7.4 GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.7.5 GlaxoSmithKline Key News & Latest Developments
    7.8 Novartis
        7.8.1 Novartis Company Summary
        7.8.2 Novartis Business Overview
        7.8.3 Novartis HER2-negative Breast Cancer Treatment Major Product Offerings
        7.8.4 Novartis HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.8.5 Novartis Key News & Latest Developments
    7.9 Merck
        7.9.1 Merck Company Summary
        7.9.2 Merck Business Overview
        7.9.3 Merck HER2-negative Breast Cancer Treatment Major Product Offerings
        7.9.4 Merck HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.9.5 Merck Key News & Latest Developments
    7.10 Eli Lilly
        7.10.1 Eli Lilly Company Summary
        7.10.2 Eli Lilly Business Overview
        7.10.3 Eli Lilly HER2-negative Breast Cancer Treatment Major Product Offerings
        7.10.4 Eli Lilly HER2-negative Breast Cancer Treatment Revenue in Global Market (2018-2023)
        7.10.5 Eli Lilly Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

HER2-negative Breast Cancer Treatment Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?